XML 72 R48.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of Accounting Policies - Effects of Adopting ASC 606 (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Jan. 01, 2018
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]        
Sales $ 42,294 $ 40,122 $ 39,807  
Cost of sales 13,509 12,912 14,030  
Income before taxes 8,701 6,521 4,659  
Taxes on Income 2,508 4,103 718  
Net Income Attributable to Merck & Co., Inc. 6,220 2,394 $ 3,920  
Assets        
Accounts receivable 7,071 6,873    
Inventories 5,440 5,096    
Liabilities        
Accrued and other current liabilities 10,151 10,427    
Income taxes payable 1,971 708    
Equity        
Retained earnings 42,579 $ 41,350    
Amounts Without Adoption of ASC 606        
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]        
Sales 42,292      
Cost of sales 13,503      
Income before taxes 8,705      
Taxes on Income 2,509      
Net Income Attributable to Merck & Co., Inc. 6,223      
Assets        
Accounts receivable 7,058      
Inventories 5,447      
Liabilities        
Accrued and other current liabilities 10,148      
Income taxes payable 1,970      
Equity        
Retained earnings 42,577      
ASU 2014-09 (Revenue) | Effects of Adopting ASC 606        
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]        
Sales (2)      
Cost of sales (6)      
Income before taxes 4      
Taxes on Income 1      
Net Income Attributable to Merck & Co., Inc. 3      
Assets        
Accounts receivable (13)     $ 5
Inventories 7      
Liabilities        
Accrued and other current liabilities (3)      
Income taxes payable (1)      
Equity        
Retained earnings $ (2)     $ 5